BI-4020
BI-4020 is a potent, orally bioavailable, and non-covalent fourth-generation EGFR tyrosine kinase inhibitor. It demonstrates high activity against resistant triple (del19/T790M/C797S) and double mutants, with selectivity over wild-type EGFR and a favorable kinome/DMPK profile. This profile supports its investigation in preclinical models of non-small cell lung cancer (NSCLC) driven by EGFR mutations.
Product Specifications
CAS Number
2664214-60-0
Product Name Alternative
BI4020, BI-4020, BI 4020, inhibit, EGFR (del19), EGFR (del19/T790M), EGFR (del19/T790M/C797S), EGFR, EGFR (wt), EGFRdel19, EGFRdel19 T790M, EGFRdel19 T790M C797S, EGFRWT, Epidermal growth factor receptor, ErbB-1, Inhibitor, HER1
Field of Research
Cardiovascular Research, Signal Transduction
Purity
97.21% (May vary between batches)
Solubility
DMSO:240 mg/mL (442.25 mM) ;10% DMSO+40% PEG300+5% Tween 80+45% Saline:5 mg/mL (9.21 mM)
Smiles
C[C@@H]1CCCOc2c (cnn2C) -c2cc (cc (C) n2) C (=O) \N=C2/Nc3ccc (CN4CCN (C) CC4) cc3N2C1
Molecular Formula
C30H38N8O2
Molecular Weight
542.68
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
